XM does not provide services to residents of the United States of America.
E
E

EurofinsScientific

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

European shares fall as Airbus leads aerospace sell-off

UPDATE 2-European shares fall as Airbus leads aerospace sell-off For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Airbus tumbles on profit warning Industrials lead sell-off Novo Nordisk hits record high after Wegovy gets China approval STOXX 600 down 0.2% Updated at 1600 GMT By Jesus Calero, Shashwat Chauhan and Shristi Achar A June 25 (Reuters) - European shares declined on Tuesday as Airbus tumbled after a profit warning and sparked an
A
A
E
M
N
R
E
F
G

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch June 25 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. WENDEL MWDP.PA The company said it was in discussions with Safran to acquire Preligens, a leader in artificial intelligence for aerospace and defense.
A
E
S
W
A
F
N
U

Eurofins denies short seller Muddy Waters' allegations after share fall

UPDATE 2-Eurofins denies short seller Muddy Waters' allegations after share fall Shares fell as much as 25% on Monday after short seller's report Says claims are "inaccurate, irrelevant, biased and/or misleading" Shares up 4.7% in early trade Adds detail from Eurofins response June 25 (Reuters) - Lab testing firm Eurofins EUFI.PA on Tuesday rejected allegations made a day earlier by short seller Muddy Waters which questioned its financial reporting and hit its shares, saying it was confident in
E

Eurofins denies short seller allegations after share slump

Eurofins denies short seller allegations after share slump June 25 (Reuters) - Eurofins EUFI.PA on Tuesday denied allegations of financial wrongdoing made by short seller Muddy Waters that had sent its shares down around 20% on Monday, adding it would provide a detailed list on the facts raised in the report 'in due course'. "It is Eurofins' view that entirety of allegations and insinuations contained therein is either inaccurate, irrelevant, biased and/or misleading," the lab testing firm said
E

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.